DGAP-News

Sangui BioTech International Inc.: Series of preclinical trials concluded successfully

DGAP-News: Sangui BioTech International Inc. / Key word(s): Research
Update
Sangui BioTech International Inc.: Series of preclinical trials
concluded successfully

18.03.2015 / 10:00

---------------------------------------------------------------------

Sangui Biotech: Series of preclinical trials concluded successfully

Witten, Germany, March 18, 2015 - The research team embracing SanguiBioTech
GmbH, the Excellence Cluster Cardio Pulmonary System (ECCPS) and TransMIT
Gesellschaft für Technologietransfer mbH has now successfully concluded a
series of preclinical trials at Giessen University dedicated to the
indication of septic shock. The interim results which were communicated in
November 2014 were now confirmed on a statistically significant basis. The
hemoglobin based product SBT102 developed by SanguiBioTech does improve the
oxygen supply of vital organs. The research team under the direction of
professors Ralph T. Schermuly and Ardeshir Ghofrani comes to the
conclusion: "The intraperitoneal application of SBT102 is an innovative and
effective therapy to avoid tissue hypoxemia. The restoration of intestinal
oxygenation will have an impact on tissue integrity and eventually on
patient survival." A comprehensive scientific report is currently being
elaborated.

Severe sepsis and septic shock are among the most common causes of death in
intensive care. Studies in Germany showed that sepsis had a prevalence of
11% in German intensive care units and a 90-day mortality of 54%. Direct
cost associated with treating these patients amount to around EUR1.77 bn.,
representing 30% of the intensive care budget. Indirect cost are being
estimated to reach around EUR4.5 bn. It is to be assumed, therefore, that
the total cost relating to severe sepsis and septic shock for the German
health system amount to approx. EUR6.3 bn. per year.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

ECCPS is an organization set up jointly by the universities of Frankfurt
and Giessen together with the Max Planck Institute for Heart and Lung
Research in Bad Nauheim. It ranks among the world's leading organizations
of this type. This unique centre for translational medicine combines
innovative medical research in the field of heart and lung diseases with
their practical advancements based on preclinical and clinical studies. Its
aim is to work together with industry on developing innovative drugs and
substances.

TransMIT Gesellschaft für Technologietransfer mbH (www.transmit.de) being
the unit in charge of technology transfer at Justus-Liebig University in
Giessen is involved in carrying out this project.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]



---------------------------------------------------------------------

18.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


334353 18.03.2015